News | March 24, 2014

RaySearch Secures Distribution of RayStation in Australia and New Zealand

RaySearch, RayStation, radiation therapy

March 24, 2013 – RaySearch Laboratories AB has entered into an exclusive distribution agreement with AlphaXRT (formerly CMS Alphatech) based in Sydney, Australia and Auckland, New Zealand. The agreement means that AlphaXRT will be fully responsible for marketing, sales and service of RaySearch’s proprietary treatment planning system RayStation in Australia and New Zealand starting April 1, 2014.

Australasia is a well-established, world renowned and growing radiation therapy market. AlphaXRT is a leading distributor of software and equipment used in the treatment of cancer and represents a wide range of international suppliers. The company was founded in 1990 and the sales and support team at AlphaXRT are experienced in the field of radiation therapy treatment planning systems and serve all radiation therapy centers in Australia and New Zealand.

“RaySearch has a longstanding reputation in treatment planning solutions and RayStation is the leading independent treatment planning system available. We look forward to working with RaySearch to promote RayStation to our customers in the region”, says Richard Neale, Managing Director of AlphaXRT.

“AlphaXRT is a leading distributor of advanced radiation therapy equipment with a long track record, so we are of course delighted that they have elected to partner with RaySearch. We will now work closely together with AlphaXRT’s experienced experts to satisfy the needs of existing and future RayStation customers,” says Johan Löf, CEO of RaySearch.

For more information about RaySearch, visit www.raysearchlabs.com.

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve